Legend Biotech Corporation
LEGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.25 | -2.21 | -3.48 | -1.28 |
| FCF Yield | -5.32% | -7.85% | -5.60% | -7.48% |
| EV / EBITDA | -26.85 | -9.10 | -8.33 | -6.92 |
| Quality | ||||
| ROIC | -24.21% | -26.78% | -43.88% | -46.84% |
| Gross Margin | 62.60% | 49.42% | 44.14% | -248.97% |
| Cash Conversion Ratio | 0.91 | 0.76 | 0.45 | 0.49 |
| Growth | ||||
| Revenue 3-Year CAGR | 75.02% | 60.61% | 15.98% | 3.65% |
| Free Cash Flow Growth | 61.99% | -87.13% | 9.48% | 3.04% |
| Safety | ||||
| Net Debt / EBITDA | -0.56 | 1.99 | 1.20 | 1.44 |
| Interest Coverage | -14.03 | -20.17 | -42.22 | -436.69 |
| Efficiency | ||||
| Inventory Turnover | 9.81 | 7.42 | 6.31 | 179.16 |
| Cash Conversion Cycle | 51.99 | 199.21 | 16.13 | 199.13 |